Compare · ARTV vs RVMD
ARTV vs RVMD
Side-by-side comparison of Artiva Biotherapeutics Inc. (ARTV) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARTV and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD is the larger of the two at $36.04B, about 148.8x ARTV ($242.2M).
- Over the past year, ARTV is up 502.5% and RVMD is up 323.3% - ARTV leads by 179.1 points.
- RVMD has been more active in the news (22 items in the past 4 weeks vs 5 for ARTV).
- RVMD has more recent analyst coverage (25 ratings vs 7 for ARTV).
- Company
- Artiva Biotherapeutics Inc.
- Revolution Medicines Inc.
- Price
- $9.79+4.59%
- $169.50+2.23%
- Market cap
- $242.2M
- $36.04B
- 1M return
- +22.84%
- +10.19%
- 1Y return
- +502.46%
- +323.31%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2020
- News (4w)
- 5
- 22
- Recent ratings
- 7
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest ARTV
- Artiva Biotherapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- Director Ra Capital Management, L.P. bought $4,599,903 worth of shares (531,326 units at $8.66) (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Artiva Biotherapeutics Inc.
- Director Ra Capital Management, L.P. bought $7,650,148 worth of shares (1,027,722 units at $7.44) (SEC Form 4)
- Artiva Biotherapeutics Highlights AlloNK® Data Presented at EULAR 2026, FDA RMAT Designation in Refractory Rheumatoid Arthritis and Webcast Today
- The $13 Million Company Teaching the Immune System to Hunt Cancer
- Large owner Gc Corp. bought $16,499,992 worth of shares (1,432,291 units at $11.52) (SEC Form 4)
- Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
- SVP, Research and Development Raymon Heather sold $27,879 worth of shares (3,095 units at $9.01), decreasing direct ownership by 2% to 148,228 units (SEC Form 4) to satisfy withholding tax
- Chief Tech Operations Officer Horan Christopher sold $63,073 worth of shares (7,002 units at $9.01), decreasing direct ownership by 2% to 293,450 units (SEC Form 4) (for withholding tax)
Latest RVMD
- Director Kim Lorence H. was granted 1,191 shares, increasing direct ownership by 2% to 74,281 units (SEC Form 4)
- Director Borisy Alexis was granted 1,191 shares, increasing direct ownership by 0.05% to 2,340,075 units (SEC Form 4)
- Director Anderson Elizabeth M was granted 1,191 shares, increasing direct ownership by 14% to 9,406 units (SEC Form 4)
- Director Horning Sandra was granted 1,191 shares, increasing direct ownership by 1% to 97,765 units (SEC Form 4)
- Director Clyburn Frank was granted 1,191 shares, increasing direct ownership by 12% to 10,929 units (SEC Form 4)
- Director Patel Sushil was granted 1,191 shares, increasing direct ownership by 5% to 24,281 units (SEC Form 4)
- Director Borellini Flavia was granted 1,191 shares, increasing direct ownership by 5% to 26,215 units (SEC Form 4)
- Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer
- SEC Form 8-K filed by Revolution Medicines Inc.
- Revolution Medicines Announces Planned Leadership Transition for Steve Kelsey, M.D.